Complete financial analysis of Cresco Labs Inc. (CRLBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cresco Labs Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Vizsla Silver Corp. (VZLA) Income Statement Analysis – Financial Results
- Shen Zhen Australis Electronic Technology Co.,Ltd. (300940.SZ) Income Statement Analysis – Financial Results
- PT Tempo Scan Pacific Tbk (TSPC.JK) Income Statement Analysis – Financial Results
- Jenscare Scientific Co., Ltd. (9877.HK) Income Statement Analysis – Financial Results
- ShiFang Holding Limited (1831.HK) Income Statement Analysis – Financial Results
Cresco Labs Inc. (CRLBF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.crescolabs.com
About Cresco Labs Inc.
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. As of January 27, 2022, it owned and operated 48 dispensaries. The company was founded in 2013 and is headquartered in Chicago, Illinois.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 770.89M | 842.68M | 821.68M | 476.25M | 128.53M | 43.25M | 10.31M | 3.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 441.00M | 435.67M | 415.34M | 192.31M | 64.45M | 2.84M | 9.16M | 14.57 | 61.11 | 82.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 329.89M | 407.01M | 406.35M | 283.94M | 64.08M | 40.42M | 1.15M | 3.16M | -61.11 | -82.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 42.79% | 48.30% | 49.45% | 59.62% | 49.86% | 93.45% | 11.17% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 1.99M | 370.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 36.81M | 54.99M | 40.34M | 160.94M | 77.15M | 29.16M | 44.42K | 42.84K | 49.32K | 49.32K | 205.78K | 341.29K | 311.56K | 338.34K | 439.16K | 300.52K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 8.30M | 15.58M | 29.73M | 19.03M | 12.63M | 2.05M | 455.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.45K | 8.44K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31.81K | 16.46K |
| SG&A | 259.81M | 350.65M | 317.80M | 179.97M | 89.78M | 31.21M | 44.42K | 42.84K | 49.32K | 49.32K | 205.78K | 341.29K | 311.56K | 338.34K | 440.60K | 308.96K | 673.66K | 442.67K | 1.56M | 437.22K | 244.28K | 130.92K | 45.36K | 31.81K | 16.46K |
| Other Expenses | 151.02M | -572.00K | 753.00K | 48.13M | 8.56M | 27.00K | 663.85 | 9.23K | 9.91K | 9.09K | 53.77K | 70.09K | 227.95K | 253.46K | 22.40K | -303.78K | 1.07K | 21.70K | 766.91 | 1.16K | -119.15K | 127.65K | 209.13K | 319.18K | 231.94K |
| Operating Expenses | 435.36M | 350.08M | 318.56M | 228.10M | 98.34M | 33.82M | 44.42K | 42.86K | -55.99K | 60.27K | 208.32K | 380.51K | 339.52K | 338.89K | 440.98K | 310.51K | 674.73K | 444.15K | 1.56M | 441.25K | 244.28K | 130.92K | 89.48K | 350.99K | 248.41K |
| Cost & Expenses | 858.71M | 785.75M | 733.89M | 420.41M | 162.79M | 36.65M | 44.42K | 42.86K | -55.99K | 60.27K | 208.32K | 380.51K | 339.52K | 338.89K | 440.98K | 310.51K | 674.73K | 444.15K | 1.56M | 441.25K | 244.28K | 130.92K | 89.48K | 350.99K | 248.41K |
| Interest Income | 2.42M | 679.00K | 938.00K | 1.41M | 1.58M | 89.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.96K | 18.40K | 0.00 | 1.56K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 63.24M | 58.52M | 52.15M | 40.91M | 9.46M | 89.00K | 41.60K | 30.81K | 26.49K | 33.62K | 48.18K | 39.92K | 39.75K | 49.55K | 32.63K | 3.78K | 0.00 | 1.10M | 0.00 | 0.00 | 182.35K | 0.00 | 0.00 | 132.58K | 0.69 |
| Depreciation & Amortization | 70.57M | 55.44M | 44.55M | 38.70M | 12.19M | 2.17M | 646.00K | 14.57 | 61.53 | 82.48 | 116.50 | 158.61 | 194.51 | 542.64 | 374.50 | 1.55K | 1.07K | 1.49K | 766.91 | 1.61 | 126.41K | 1.31 | 44.13K | 46.75K | 34.57K |
| EBITDA | -14.62M | -10.24M | -157.04M | 6.75M | -30.09M | 9.66M | -3.48M | -33.61K | 73.43K | -84.07K | -154.56K | -322.46K | 4.52K | -2.23M | -2.88M | -2.03M | -559.24K | -979.09K | -1.56M | -441.25K | -181.08K | -130.92K | -31.58K | -304.24K | -213.84K |
| EBITDA Ratio | -1.90% | 14.65% | 16.18% | 20.65% | -13.77% | 23.84% | -0.42% | -1.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -87.82M | 65.75M | 87.97M | 58.31M | -34.26M | 4.95M | -44.42K | -33.63K | 65.89K | -51.18K | -154.55K | -310.43K | -379.27K | -388.43K | -473.61K | -595.88K | -674.73K | -1.00M | -1.56M | -441.25K | -307.49K | -130.92K | -103.26K | -350.99K | -248.41K |
| Operating Income Ratio | -11.39% | 7.80% | 10.71% | 12.24% | -26.65% | 11.43% | -0.43% | -1.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -59.08M | -42.61M | -39.38M | -40.71M | -28.95M | -1.29M | 139.77K | 53.05K | 96.42K | -56.92K | 5.59K | 20.51K | 186.63K | -1.89M | -2.44M | -1.72M | 90.18K | -537.39K | 43.16K | 1.16K | -182.35K | 127.65K | 195.35K | -132.58K | -0.69 |
| Income Before Tax | -146.90M | -126.91M | -256.73M | 7.16M | -50.84M | 7.47M | -85.35K | -108.03K | 47.38K | -117.44K | -202.74K | -361.38K | -151.32K | -85.43K | -2.91M | -2.05M | -584.55K | -981.24K | -1.51M | -440.09K | -489.85K | -3.27K | 92.09K | -483.57K | -248.41K |
| Income Before Tax Ratio | -19.06% | -15.06% | -31.24% | 1.50% | -39.55% | 17.26% | -0.83% | -3.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 32.95M | 88.94M | 40.11M | 43.72M | 14.46M | 4.37M | -663.85 | 43.59K | -7.98K | 32.64K | 0.00 | 11.03K | -342.40K | 4.03M | 2.47M | -19.39K | -90.18K | 1.10M | -146.31K | -3.00K | 131.48K | -116.13K | -158.23K | 132.58K | 0.69 |
| Net Income | -175.52M | -215.84M | -296.83M | -36.56M | -65.30M | -1.92M | -85.35K | -108.03K | 47.38K | -117.44K | -202.74K | -361.38K | -36.87K | -2.28M | -2.91M | -2.03M | -584.55K | -981.24K | -1.37M | -438.25K | -438.97K | -14.79K | 82.52K | -483.57K | -248.41K |
| Net Income Ratio | -22.77% | -25.61% | -36.13% | -7.68% | -50.81% | -4.43% | -0.83% | -3.42% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.54 | -0.72 | -1.13 | -0.17 | -0.55 | -0.03 | -2.45 | -3.10 | 1.16 | -3.38 | -5.82 | -10.38 | -1.11 | -77.44 | -108.25 | -78.24 | -24.14 | -44.38 | -71.04 | -29.14 | -43.91 | -1.76 | 15.37 | -86.80 | -67.23 |
| EPS Diluted | -0.54 | -0.72 | -1.13 | -0.17 | -0.55 | -0.03 | -2.45 | -3.10 | 1.16 | -3.37 | -5.82 | -10.38 | -1.11 | -77.44 | -108.25 | -78.24 | -24.14 | -44.38 | -71.04 | -29.14 | -43.91 | -1.76 | 15.37 | -86.80 | -67.23 |
| Weighted Avg Shares Out | 323.82M | 298.16M | 262.33M | 210.47M | 118.32M | 59.34M | 34.79K | 34.79K | 34.79K | 34.79K | 34.81K | 34.81K | 33.17K | 29.39K | 26.89K | 25.89K | 24.21K | 22.11K | 19.24K | 15.04K | 10.00K | 8.38K | 6.21K | 5.57K | 3.70K |
| Weighted Avg Shares Out (Dil) | 323.82M | 298.16M | 262.33M | 210.47M | 118.32M | 59.34M | 34.81K | 34.81K | 34.81K | 34.81K | 34.81K | 34.81K | 33.17K | 29.39K | 26.89K | 25.89K | 24.21K | 22.11K | 19.24K | 15.04K | 10.00K | 8.38K | 6.21K | 5.57K | 3.70K |
Cannabis stocks see fifth straight week of gains ahead of earnings
Cannabis stocks on Friday booked their fifth-straight week of positive returns led by the Advisorshares Pure US Cannabis ETF (MSOS) which gained 12% to finish the week at about $10.30. The Advisorshares Pure Cannabis ETF (YOLO), which provides exposure to...
Top US Marijuana Stocks for February 2024 Watchlist
As we step into February 2024, the cannabis industry and top marijuana stocks continue to show vibrant growth. This sector has captured investors' attention worldwide. The U.S. and global markets are expanding rapidly. In addition, legalization efforts are propelling this...
Cresco Labs Promotes Greg Butler to President
CHICAGO--(BUSINESS WIRE)--Cresco Labs Promotes Greg Butler to President.
Here Are 3 Marijuana Stocks To Watch Today
Investing in the best marijuana stocks can be a challenge at times. For example, you would think the company whos more successful would do better in the stock market. With the cannabis sector that is not always the case. There...
Alan Brochstein On Rescheduling Overexcitement, MSOs, Canada And The Burden Of 280E
Alan Brochstein thinks investors are overly excited about the recent cannabis rescheduling announcement, which is not significant news. The burden of 280E and other financial challenges, debt and income tax payable.
The Best Marijuana Stocks To Trade This Week
So far the start of 2024 has been a momentum builder for marijuana stocks. Much of which is built off of speculation of what will take place in the future. From 2018 to 2024 the demand for cannabis has grown...
Cannabis stocks move sharply higher as details emerge on rescheduling recommendation
The release of documents that support a recommendation by the U.S. Department of Health and Human Services to lower the classification of cannabis under federal law to Schedule III from Schedule I ignited a rally in cannabis stocks on Tuesday.
As Tilray, Curaleaf, Cresco Labs, MSOS ETF stocks jump, old risks remain
Cannabis stocks and ETFs are having a good time after some regulatory movements in the past few days. The AdvisorShares Pure US Cannabis ETF (MSOS) surged by over 10% on Friday and was up by more than 7% in the...
Rising High: Top Cannabis Penny Stocks Below $2 to Watch Now
The buzz around marijuana penny stocks under $2 is growing louder this week, and it's not hard to see why. These stocks are a hotspot for investors looking for a mix of thrill and potential gains in the stock market....
High Potential: Leading U.S. Marijuana Stocks in January 2024
As we step into 2024, the U.S. marijuana industry and top marijuana stocks are buzzing with potential, making it a hot topic for investors. The landscape is changing rapidly, thanks to the growing acceptance and legalization of cannabis across many...
Source: https://incomestatements.info
Category: Stock Reports